

REPORT TO THE LEGISLATURE
Pursuant to P.A. 166 of 2022
Article 2, Section 604
Hepatitis C Treatment Report

Sec. 604. (1) Funds appropriated in part 1 for Hepatitis C treatment shall be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used shall be used only to purchase specialty medication for Hepatitis C treatment. By February 15, the department shall issue a report for the prior fiscal year showing the total amount spent on specialty medication for the treatment of Hepatitis C, the number of prisoners who were treated, the amount of any rebates that were received from the purchase of specialty medication, and what outstanding rebates are expected to be received.

(2) The report must include the Hepatitis C status of all incoming prisoners and the number of prisoners who are reinfected while incarcerated and require retreatment for Hepatitis C. The report must also include the number of those treated and released and then retreated upon reincarceration.

The total average monthly prisoner census for FY2022 was 32,287.

	# of Prisoners that started treatment during QTR	Total # of prisoners in Treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR	Total rebate rec'd	Total rebate expected
1st QTR FY 2022	138	279	159	\$ 2,333,698	\$ 27,133	\$ 28,068
2nd QTR FY 2022	184	300	149	\$ 2,604,953	\$ 38,955	\$ 25,213
3rd QTR FY 2022	125	264	175	\$ 2,148,450	\$ 37,754	\$ 46,020
4th QTR FY 2022	118	207	105	\$ 1,804,893	\$ 36,696	\$ 36,045

Fibrosis Stage of Incoming, Treated Prisoners					
	Stage 0	Stage 1	Stage 2	Stage 3	Stage 4
Number of Prisoners	119	274	84	62	26

*During FY2022, five (5) prisoners received a re-treatment for HCV infection after a previously successful treatment and then became reinfected. Of those five, approximately two (2) of those occurred in MDOC custody.